These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36519977)

  • 1. Coordinate-Dependent Drift-Diffusion Reveals the Kinetic Intermediate Traps of Top7-Based Proteins.
    Oliveira RJ
    J Phys Chem B; 2022 Dec; 126(51):10854-10869. PubMed ID: 36519977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotinylation Eliminates the Intermediate State of Top7 Designed with an HIV-1 Epitope.
    Oliveira RJ
    J Phys Chem B; 2022 Sep; 126(38):7331-7342. PubMed ID: 36121918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of biotinylation on the ability of a computer designed protein to detect B-cells producing anti-HIV-1 2F5 antibodies.
    Coêlho DF; Ferraz MVF; Marques ETA; Lins RD; Viana IFT
    J Mol Graph Model; 2019 Dec; 93():107442. PubMed ID: 31479948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing cooperativity into the designed protein Top7.
    Yadahalli S; Gosavi S
    Proteins; 2014 Mar; 82(3):364-74. PubMed ID: 23966061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition between native topology and nonnative interactions in simple and complex folding kinetics of natural and designed proteins.
    Zhang Z; Chan HS
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2920-5. PubMed ID: 20133730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native topology of the designed protein Top7 is not conducive to cooperative folding.
    Zhang Z; Chan HS
    Biophys J; 2009 Feb; 96(3):L25-7. PubMed ID: 19186118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.
    Guenaga J; Dosenovic P; Ofek G; Baker D; Schief WR; Kwong PD; Karlsson Hedestam GB; Wyatt RT
    PLoS One; 2011 Jan; 6(1):e16074. PubMed ID: 21297864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folding of Top7 in unbiased all-atom Monte Carlo simulations.
    Mohanty S; Meinke JH; Zimmermann O
    Proteins; 2013 Aug; 81(8):1446-56. PubMed ID: 23553942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
    Alam SM; Liao HX; Dennison SM; Jaeger F; Parks R; Anasti K; Foulger A; Donathan M; Lucas J; Verkoczy L; Nicely N; Tomaras GD; Kelsoe G; Chen B; Kepler TB; Haynes BF
    J Virol; 2011 Nov; 85(22):11725-31. PubMed ID: 21917975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
    J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of structure-specific antibodies by epitope scaffolds.
    Ofek G; Guenaga FJ; Schief WR; Skinner J; Baker D; Wyatt R; Kwong PD
    Proc Natl Acad Sci U S A; 2010 Oct; 107(42):17880-7. PubMed ID: 20876137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
    Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
    J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
    Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single molecule force spectroscopy reveals the context dependent folding pathway of the C-terminal fragment of Top7.
    Li J; Chen G; Guo Y; Wang H; Li H
    Chem Sci; 2020 Dec; 12(8):2876-2884. PubMed ID: 34164053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
    Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
    Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.
    Hu B; Liao HX; Alam SM; Goldstein B
    PLoS Comput Biol; 2014 Jan; 10(1):e1003431. PubMed ID: 24499928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
    Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
    J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.